Epstein-Barr virus latent membrane protein 1 peptide-HLA complex (LMP1-HLA complex)

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) peptide-HLA complex is a highly specific tumor-associated antigen found on the surface of EBV-infected malignant cells. LMP1 is a primary oncogene of EBV that mimics CD40 signaling to promote cell survival and proliferation, but because it is a transmembrane protein, its intracellular and transmembrane fragments are processed and presented by Human Leukocyte Antigen (HLA) molecules. These peptide-HLA complexes, particularly those restricted by HLA-A*02:01 (such as the YLQQNWWTL epitope), serve as critical targets for adoptive T-cell therapies and TCR-engineered cells. Unlike traditional surface antigens, these complexes allow the immune system to 'see' intracellular viral proteins that are essential for the oncogenic phenotype of the tumor. Targeting these complexes is a primary strategy in treating EBV-associated malignancies like nasopharyngeal carcinoma and Hodgkin lymphoma, where LMP1 expression is prevalent. Current therapeutic development focuses on enhancing the affinity of T-cell receptors (TCRs) or developing TCR-like antibodies that can distinguish these viral pMHCs from self-peptides to minimize off-target effects.

Other names

EBV LMP1-MHC complexLMP1-derived peptide-HLA complexYLQQNWWTL-HLA-A*02:01 complexLMP1 pMHC

Therapeutic agents, such as TCR-engineered T cells or TCR-like antibodies, specifically recognize and bind to the LMP1 peptide presented within the HLA groove on the surface of tumor cells. This binding triggers T-cell mediated cytotoxicity, leading to the release of perforins and granzymes that induce apoptosis in the EBV-infected malignant cells.